Pre-Market News Analysis on: Biomed Realty Trust (NYSE:BMR), Carnival (NYSE:CCL), Juno Therapeutics (NASDAQ:JUNO), Hersha Hospitality Trust (NYSE:HT)

Pre-Market News Analysis on: Biomed Realty Trust (NYSE:BMR), Carnival (NYSE:CCL), Juno Therapeutics (NASDAQ:JUNO), Hersha Hospitality Trust (NYSE:HT)

- in Business & Finance
0

On Thursday, Biomed Realty Trust Inc (NYSE:BMR)’s shares inclined 1.70% to $20.34.

BioMed Realty Trust, Inc. (BMR) declared that its board of directors has declared a second quarter 2015 dividend of $0.26 per share of common stock. The dividend is equivalent to an annualized dividend of $1.04 per common share.

The common stock dividend is payable on July 15, 2015 to stockholders of record at the close of business on June 30, 2015.

BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT) that focuses on providing real estate to the life science industry in the United States. Its tenants primarily comprise biotechnology and pharmaceutical companies, scientific research institutions, government agencies, and other entities involved in the life science industry. The company owns or has interests in 72 properties, representing 119 buildings with about 11.0 million rentable square feet. Its properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania, and New York/New Jersey.

Carnival Corp (NYSE:CCL)’s shares gained 2.19% to $48.62.

Holland America Line a division of Carnival Corp (CCL). Holland America Line was presented with a Port Metro Vancouver 2014 Blue Circle Award for its ongoing commitment to sustainability. The award is bestowed on companies with the highest level of participation in Port Metro Vancouver’s EcoAction Program and that strive to reduce emissions and shrink their carbon footprint.

Holland America Line was one of 16 companies to receive the honor and one of just four cruise lines. Holland America Line has won the award every year since its inception in 2009.

Carnival Corporation operates as a cruise company worldwide. It provides vacations to various cruise destinations. The company offers cruise services under the Carnival Cruise Lines, Holland America Line, Princess Cruises, and Seabourn brand names in North America; and AIDA Cruises, Costa Cruises, Cunard, and P&O Cruises names in Europe, Australia, and Asia. It operates 100 cruise ships. It also owns and operates 12 hotels or lodges, and about 300 motor coaches and 20 glass-domed railcars.

At the end of Thursday’s trade, Juno Therapeutics Inc (NASDAQ:JUNO)‘s shares surged 1.29% to $51.99.

Juno Therapeutics Inc (JUNO) might not be turning a profit yet, but that’s no problem for CEO Hans Bishop’s personal bottom line.

Bishop is the 11th highest-paid CEO in the country, according to Bloomberg’s Pay Index, a daily ranking of the 100 top-paid executives. His pay package was worth $88.2 million at the end of 2014, Bloomberg stated Thursday, in a combination of salary, stock options and restricted shares. That was worth $7.3 million before Juno’s initial public offering in December.

Juno isn’t the only biotech to show up near the top of the list. CEO pay at Santa Monica, Calif.-based Kite Pharma and Waltham, Mass.-based Radius Health Inc. topped $95 million and $33.5 million, respectively.

Juno and Kite develop immunotherapy treatments for cancer. That’s a field investors have been excited to jump into in recent years. Immunotherapy reprograms a patient’s T cells and then infuses them back into the body, giving the immune system a boost to battle the cancer.

This treatment has been heralded in recent years as a breakthrough alternative to harsher methods, such as chemotherapy and radiation.

In small clinical trials, one of Juno’s drug candidates has achieved a 90 percent remission rate in a type of blood cancer.

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.

Hersha Hospitality Trust (NYSE:HT), ended its Thursday’s trading session with 2.14% gain, and closed at $6.45.

Hersha Hospitality Trust (HT) owner of upscale hotels in urban gateway markets, declared that the Company will release its financial results for the second quarter 2015 after the market close on Tuesday, July 28, 2015. The Company will host a conference call to talk about these results at 9:00 a.m. Eastern Time on Wednesday, July 29, 2015. Hosting the call will be Mr. Jay H. Shah, Chief Executive Officer, Mr. Neil H. Shah, President and Chief Operating Officer, and Mr. Ashish Parikh, Chief Financial Officer.

Hersha Hospitality Trust, a real estate investment trust, engages in the ownership and operation of mid scale limited service hotels in the Eastern United States. As of June 30, 2005, it owned interests in 35 hotels, counting 4 hotels owned through joint ventures in Pennsylvania, New York, New Jersey, Maryland, Georgia, Connecticut, and Massachusetts.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.

 

Leave a Reply

Your email address will not be published. Required fields are marked *